A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin et al., Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension, Eur Respir J, vol.50, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01757586

G. Simonneau, D. Montani, D. S. Celermajer, C. P. Denton, M. A. Gatzoulis et al., Haemodynamic definitions and updated clinical classification of pulmonary hypertension, Eur Respir J, 2018.

H. W. Farber, D. P. Miller, A. D. Poms, D. B. Badesch, A. E. Frost et al., Five-Year outcomes of patients enrolled in the REVEAL Registry, Chest, vol.148, pp.1043-1054, 2015.

M. Humbert, E. M. Lau, D. Montani, X. Jais, O. Sitbon et al., Advances in therapeutic interventions for patients with pulmonary arterial hypertension, Circulation, vol.130, pp.2189-2208, 2014.

N. Galie, M. Humbert, J. L. Vachiery, S. Gibbs, I. Lang et al., , 2015.

. Esc/ers, Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Respir J, vol.46, pp.903-975, 2015.

M. Humbert, O. Sitbon, and G. Simonneau, Treatment of pulmonary arterial hypertension, N Engl J Med, vol.351, pp.1425-1436, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01455600

M. Humbert, C. Guignabert, S. Bonnet, P. Dorfmuller, J. R. Klinger et al., Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives, Eur Respir J, vol.53, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02612658

C. Guignabert, S. Bailly, and M. Humbert, Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations, Expert Opin Ther Targets, vol.21, pp.181-190, 2017.

N. W. Morrell, M. A. Aldred, W. K. Chung, C. G. Elliott, W. C. Nichols et al., Genetics and genomics of pulmonary arterial hypertension, Eur Respir J, vol.53, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02137830

M. J. Goumans, A. Zwijsen, P. Ten-dijke, and S. Bailly, Bone Morphogenetic Proteins in Vascular Homeostasis and Disease, Cold Spring Harb Perspect Biol, vol.10, 2018.

M. Morikawa, R. Derynck, and K. Miyazono, TGF-beta and the TGF-beta Family: Context-Dependent Roles in Cell and Tissue Physiology, Cold Spring Harb Perspect Biol, vol.8, 2016.

S. Li, C. Shimono, N. Norioka, I. Nakano, T. Okubo et al., Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity, J Biol Chem, vol.285, pp.36645-36655, 2010.

J. D. Evans, B. Girerd, D. Montani, X. J. Wang, N. Galie et al., BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis, Lancet Respir Med, vol.4, pp.129-137, 2016.

R. D. Machado, L. Southgate, C. A. Eichstaedt, M. A. Aldred, E. D. Austin et al., Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects, Hum Mutat, vol.36, pp.1113-1127, 2015.

L. Southgate, R. D. Machado, S. Graf, and N. W. Morrell, Molecular genetic framework underlying pulmonary arterial hypertension, Nat Rev Cardiol, vol.17, pp.85-95, 2020.

B. Sztrymf, F. Coulet, B. Girerd, A. Yaici, X. Jais et al., Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation, Am J Respir Crit Care Med, vol.177, pp.1377-1383, 2008.

M. R. Ghigna, C. Guignabert, D. Montani, B. Girerd, X. Jaïs et al., BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension, Eur Respir J, 2016.

C. E. Van-der-bruggen, C. M. Happe, P. Dorfmuller, P. Trip, O. A. Spruijt et al., Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle, Circulation, vol.133, pp.1747-1760, 2016.

B. Girerd, D. Montani, F. Coulet, B. Sztrymf, A. Yaici et al., Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation, Am J Respir Crit Care Med, vol.181, pp.851-861, 2010.

S. Graf, M. Haimel, M. Bleda, C. Hadinnapola, L. Southgate et al., Nat Commun, vol.9, p.1416, 2018.

L. David, C. Mallet, S. Mazerbourg, J. J. Feige, and S. Bailly, Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells, Blood, vol.109, pp.1953-1961, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00376097

R. K. Hopper, J. R. Moonen, I. Diebold, A. Cao, C. J. Rhodes et al., Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug, vol.133, pp.1783-1794, 2016.

J. Hodgson, E. M. Swietlik, R. M. Salmon, C. Hadinnapola, I. Nikolic et al., Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension, Am J Respir Crit Care Med, vol.201, pp.575-585, 2020.

I. Nikolic, L. M. Yung, P. Yang, R. Malhotra, S. D. Paskin-flerlage et al., Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension, Am J Respir Crit Care Med, vol.199, pp.891-902, 2019.

E. R. Rochon, M. J. Krowka, S. Bartolome, G. A. Heresi, T. Bull et al., Pulmonary Vascular Complications of Liver Disease 2 Study G. BMP 9/10 in Pulmonary Vascular Complications of Liver Disease, Am J Respir Crit Care Med, 2020.

A. Yndestad, K. O. Larsen, E. Oie, T. Ueland, C. Smith et al., Elevated levels of activin A in clinical and experimental pulmonary hypertension, J Appl Physiol, vol.106, pp.1356-1364, 1985.

L. M. Yung, P. Yang, S. Joshi, Z. M. Augur, S. Kim et al., ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension, Sci Transl Med, vol.12, 2020.

N. Nickel, T. Kempf, H. Tapken, J. Tongers, F. Laenger et al., Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.178, pp.534-541, 2008.

C. A. Meadows, M. G. Risbano, L. Zhang, M. W. Geraci, R. M. Tuder et al., Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension, Chest, vol.139, pp.994-1002, 2011.

L. W. Geenen, V. Baggen, R. M. Kauling, T. Koudstaal, K. A. Boomars et al., Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension, Heart, vol.106, pp.467-473, 2020.

M. Mirna, I. Rohm, P. Jirak, B. Wernly, L. Baz et al., Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH), Heart Lung Circ, vol.29, pp.337-344, 2020.

G. Li, Y. Li, X. Q. Tan, P. Jia, J. Zhao et al., Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease, Pediatr Cardiol, vol.38, pp.1620-1626, 2017.

B. Gore, M. Izikki, O. Mercier, L. Dewachter, E. Fadel et al., Key role of the endothelial TGF-beta/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension, PLoS One, vol.9, p.100310, 2014.

Y. Yan, X. J. Wang, S. Q. Li, S. H. Yang, Z. C. Lv et al., Elevated levels of plasma transforming growth factor-beta1 in idiopathic and heritable pulmonary arterial hypertension, Int J Cardiol, vol.222, pp.368-374, 2016.

N. Selimovic, C. H. Bergh, B. Andersson, E. Sakiniene, H. Carlsten et al., Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension, Eur Respir J, vol.34, pp.662-668, 2009.

R. Malhotra, S. Paskin-flerlage, R. T. Zamanian, P. Zimmerman, J. W. Schmidt et al., Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension, Pulm Circ, vol.3, pp.369-380, 2013.

C. Atkinson, S. Stewart, P. D. Upton, R. Machado, J. R. Thomson et al., Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor, Circulation, vol.105, pp.1672-1678, 2002.

L. Du, C. C. Sullivan, D. Chu, A. J. Cho, M. Kido et al., Signaling molecules in nonfamilial pulmonary hypertension, N Engl J Med, vol.348, pp.500-509, 2003.

A. Richter, M. E. Yeager, A. Zaiman, C. D. Cool, N. F. Voelkel et al., Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.170, pp.1340-1348, 2004.

X. Yang, L. Long, M. Southwood, N. Rudarakanchana, P. D. Upton et al., Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension, Circ Res, vol.96, pp.1053-1063, 2005.

J. Yang, X. Li, Y. Li, M. Southwood, L. Ye et al., Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells, Am J Physiol Lung Cell Mol Physiol, vol.305, pp.312-321, 2013.

D. Zabini, E. Granton, Y. Hu, M. Z. Miranda, U. Weichelt et al., Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition, Am J Respir Crit Care Med, vol.197, pp.244-260, 2018.

M. D. Botney, L. Bahadori, and L. I. Gold, Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta, Am J Pathol, vol.144, pp.286-295, 1994.

N. Ricard, L. Tu, L. Hiress, M. Huertas, A. Phan et al., Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension, Circulation, vol.129, pp.1586-1597, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02578269

N. Nickel, D. Jonigk, T. Kempf, C. L. Bockmeyer, L. Maegel et al., GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells, Respir Res, vol.12, p.62, 2011.

J. Bordenave, L. Tu, N. Berrebeh, R. Thuillet, A. Cumont et al., Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension, Arterioscler Thromb Vasc Biol, vol.40, pp.766-782, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02454982

L. Tu, A. Desroches-castan, C. Mallet, L. Guyon, A. Cumont et al., Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension, Circ Res, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02007505

L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton et al., Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease, Circulation, vol.119, pp.566-576, 2009.

M. Thomas, C. Docx, A. M. Holmes, S. Beach, N. Duggan et al., Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline, Am J Pathol, vol.174, pp.380-389, 2009.

L. Yang, N. Yin, L. Hu, H. Fan, D. Yu et al., Sildenefil increases connexin 40 in smooth muscle cells through activation of BMP pathways in pulmonary arterial hypertension, Int J Clin Exp Pathol, vol.7, pp.4674-4684, 2014.

A. L. Zaiman, M. Podowski, S. Medicherla, K. Gordy, F. Xu et al., Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension, Am J Respir Crit Care Med, vol.177, pp.896-905, 2008.

M. J. Anderton, H. R. Mellor, A. Bell, C. Sadler, M. Pass et al., Induction of heart valve lesions by small-molecule ALK5 inhibitors, Toxicol Pathol, vol.39, pp.916-924, 2011.

P. Umbarkar, A. P. Singh, M. Gupte, V. K. Verma, C. L. Galindo et al., Cardiomyocyte SMAD4-Dependent TGF-beta Signaling is Essential to Maintain Adult Heart Homeostasis, JACC Basic Transl Sci, vol.4, pp.41-53, 2019.

E. Spiekerkoetter, X. Tian, J. Cai, R. K. Hopper, D. Sudheendra et al., Ten Dijke P, Rabinovitch M. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension, J Clin Invest, vol.123, pp.3600-3613, 2013.

E. Spiekerkoetter, Y. K. Sung, D. Sudheendra, V. Scott, D. Rosario et al., Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension, Eur Respir J, vol.50, 2017.

Y. Wu, A. D. Long, M. Wang, J. Liu, F. Gai et al., 4-Phenylbutyric Acid Induces Protection against Pulmonary Arterial Hypertension in Rats, PLoS One, vol.11, p.157538, 2016.

B. J. Dunmore, X. Yang, A. Crosby, S. Moore, L. Long et al., 4PBA Restores Signalling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with PAH, Am J Respir Cell Mol Biol, 2020.

K. M. Drake, B. J. Dunmore, L. N. Mcnelly, N. W. Morrell, and M. A. Aldred, Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension, Am J Respir Cell Mol Biol, vol.49, pp.403-409, 2013.

L. Long, M. L. Ormiston, X. Yang, M. Southwood, S. Graf et al., Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension, Nat Med, vol.21, pp.777-785, 2015.

M. I. Polkey, J. Praestgaard, A. Berwick, F. Franssen, D. Singh et al., Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial, Am J Respir Crit Care Med, vol.199, pp.313-320, 2019.

S. Aykul and E. Martinez-hackert, Transforming Growth Factor-beta Family Ligands Can Function as Antagonists by Competing for Type II Receptor Binding, J Biol Chem, vol.291, pp.10792-10804, 2016.

T. A. Souza, X. Chen, Y. Guo, P. Sava, J. Zhang et al., Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators, Mol Endocrinol, vol.22, pp.2689-2702, 2008.

S. A. Townson, E. Martinez-hackert, C. Greppi, P. Lowden, D. Sako et al., Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex, J Biol Chem, vol.287, pp.27313-27325, 2012.

A. Verma, R. N. Suragani, S. Aluri, N. Shah, T. D. Bhagat et al., Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes, J Clin Invest, vol.130, pp.582-589, 2020.

M. Huang, Y. L. Cheng, J. T. Zeng, X. Y. Su, and H. Liu, Inhibin alpha-subunit inhibits BMP9-induced osteogenic differentiation through blocking BMP/Smad signal and activating NF-kappaB signal in mesenchymal stem cells, J Cell Biochem, vol.119, pp.8271-8281, 2018.

M. Zhang, N. Y. Liu, X. E. Wang, Y. H. Chen, Q. L. Li et al., Activin B promotes epithelial wound healing in vivo through RhoA-JNK signaling pathway, PLoS One, vol.6, p.25143, 2011.

M. Koga, N. Engberding, A. E. Dikalova, K. H. Chang, B. Seidel-rogol et al., The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice, Am J Physiol Heart Circ Physiol, vol.305, pp.747-755, 2013.

K. Mayer, A. Buchbinder, and R. E. Morty, Activin A: a mediator governing inflammation, immunity, and repair, Am J Respir Crit Care Med, vol.185, pp.350-352, 2012.

S. Huber, F. R. Stahl, J. Schrader, S. Luth, K. Presser et al., Activin a promotes the TGF-beta-induced conversion of CD4+CD25-T cells into Foxp3+ induced regulatory T cells, J Immunol, vol.182, pp.4633-4640, 2009.

O. E. Olsen, K. F. Wader, H. Hella, A. K. Mylin, I. Turesson et al., Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B, Cell Commun Signal, vol.13, p.27, 2015.

X. Yu, X. Chen, X. D. Zheng, J. Zhang, X. Zhao et al., Growth Differentiation Factor 11 Promotes Abnormal Proliferation and Angiogenesis of Pulmonary Artery Endothelial Cells, Hypertension, vol.71, pp.729-741, 2018.

S. P. Oh, C. Y. Yeo, Y. Lee, H. Schrewe, M. Whitman et al., Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning, Genes Dev, vol.16, pp.2749-2754, 2002.

S. P. Oh and E. Li, The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse, Genes Dev, vol.11, pp.1812-1826, 1997.

J. Song, S. P. Oh, H. Schrewe, M. Nomura, H. Lei et al., The type II activin receptors are essential for egg cylinder growth, gastrulation, and rostral head development in mice, Dev Biol, vol.213, pp.157-169, 1999.

S. Mccroskery, M. Thomas, L. Maxwell, M. Sharma, and R. Kambadur, Myostatin negatively regulates satellite cell activation and self-renewal, J Cell Biol, vol.162, pp.1135-1147, 2003.

K. Relizani, E. Mouisel, B. Giannesini, C. Hourde, K. Patel et al., Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy, Mol Ther, vol.22, pp.1423-1433, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02881194

B. Zhao, R. J. Wall, and J. Yang, Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance, Biochem Biophys Res Commun, vol.337, pp.248-255, 2005.

J. D. Roh, R. Hobson, V. Chaudhari, P. Quintero, A. Yeri et al., Activin type II receptor signaling in cardiac aging and heart failure, Sci Transl Med, vol.11, 2019.

W. Guo, K. M. Pencina, T. Gagliano-juca, R. Jasuja, N. Morris et al., Effects of an ActRIIB.Fc Ligand Trap on Cardiac Function in Simian Immunodeficiency Virus-Infected Male Rhesus Macaques, J Endocr Soc, vol.2, pp.817-831, 2018.

M. Jerkic, M. G. Kabir, A. Davies, L. X. Yu, B. A. Mcintyre et al., Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress, Cardiovasc Res, vol.92, pp.375-384, 2011.

H. Beppu, F. Ichinose, N. Kawai, R. C. Jones, P. B. Yu et al., BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia, Am J Physiol Lung Cell Mol Physiol, vol.287, pp.1241-1247, 2004.

A. Hautefort, P. Mendes-ferreira, J. Sabourin, G. Manaud, T. Bertero et al., Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension, Circulation, vol.139, pp.932-948, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02346975

M. Toporsian, M. Jerkic, Y. Q. Zhou, M. G. Kabir, L. X. Yu et al., Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia, Arterioscler Thromb Vasc Biol, vol.30, pp.509-517, 2010.

K. H. Hong, Y. J. Lee, E. Lee, S. O. Park, C. Han et al., Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension, Circulation, vol.118, pp.722-730, 2008.

C. Han, K. H. Hong, Y. H. Kim, M. J. Kim, C. Song et al., SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension, Hypertension, vol.61, pp.1044-1052, 2013.

J. West, J. Harral, K. Lane, Y. Deng, B. Ickes et al., Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions, Am J Physiol Lung Cell Mol Physiol, vol.295, pp.744-755, 2008.

Z. Huang, D. Wang, K. Ihida-stansbury, P. L. Jones, and J. F. Martin, Defective pulmonary vascular remodeling in Smad8 mutant mice, Hum Mol Genet, vol.18, pp.2791-2801, 2009.

L. Anderson, J. W. Lowery, D. B. Frank, T. Novitskaya, M. Jones et al., Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension, Am J Physiol Regul Integr Comp Physiol, vol.298, pp.833-842, 2010.

D. B. Frank, A. Abtahi, D. J. Yamaguchi, S. Manning, Y. Shyr et al., Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension, Circ Res, vol.97, pp.496-504, 2005.

Y. F. Chen, J. A. Feng, P. Li, D. Xing, Y. Zhang et al., Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling, J Appl Physiol, vol.100, pp.564-571, 1985.

E. Cahill, C. M. Costello, S. C. Rowan, S. Harkin, K. Howell et al., Gremlin plays a key role in the pathogenesis of pulmonary hypertension, Circulation, vol.125, pp.920-930, 2012.

D. B. Frank, J. Lowery, L. Anderson, M. Brink, J. Reese et al., Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature, Am J Physiol Lung Cell Mol Physiol, vol.294, pp.98-109, 2008.

Y. Song, J. E. Jones, H. Beppu, J. F. Keaney, J. Loscalzo et al., Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice, Circulation, vol.112, pp.553-562, 2005.

W. Tian, X. Jiang, Y. K. Sung, E. Shuffle, T. H. Wu et al., Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation, Circulation, vol.140, pp.1409-1425, 2019.

Y. Xing, S. Zhao, Q. Wei, S. Gong, X. Zhao et al., A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels, Eur Respir J, vol.51, 2018.

L. M. Yung, I. Nikolic, S. D. Paskin-flerlage, R. S. Pearsall, R. Kumar et al., A Selective Transforming Growth Factor-beta Ligand Trap Attenuates Pulmonary Hypertension, Am J Respir Crit Care Med, vol.194, pp.1140-1151, 2016.

L. Tu, A. Desroches-castan, C. Mallet, L. Guyon, A. Cumont et al., Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension, Circ Res, vol.124, pp.846-855, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02007505

L. Ciuclan, K. Sheppard, L. Dong, D. Sutton, N. Duggan et al., Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice, Am J Pathol, vol.183, pp.1461-1473, 2013.

A. M. Reynolds, M. D. Holmes, S. M. Danilov, and P. N. Reynolds, Targeted gene delivery of BMPR2 attenuates pulmonary hypertension, Eur Respir J, vol.39, pp.329-343, 2012.

A. M. Reynolds, W. Xia, M. D. Holmes, S. J. Hodge, S. Danilov et al., Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension, Am J Physiol Lung Cell Mol Physiol, vol.292, pp.1182-1192, 2007.

, Alk1 +/-mice Bmpr2 +/-mice carrying a mutant allele lacking exons 4 and 5

, Bmpr2 +/R899X mice Bmpr2 +/?71 and Bmpr2 +/?140 rats Eng +/-mice L1cre + ; Bmpr2 f/f and L1cre + ; Bmpr2 f/+ mice L1Cre + ; Smad1 f/f mice SM22-rtTA x TetO 7 -BMPR2 R899X mice Smad8 lacZ +/? and Smad8 lacZ +/? mice Tagln-Cre +

, Bmpr2, Tgfbr1 (encoding ALK5), Tgfbr2 Perinatal lethality in homozygous KO mice: Acvr2b (encoding ActRIIB), p.3